Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 57

Results For "Access"

2301 News Found

Novartis to launch DTP platform for Cosentyx in US
Supply Chain | October 01, 2025

Novartis to launch DTP platform for Cosentyx in US

Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers


Pfizer agrees to slash prescription drug prices for Americans
News | October 01, 2025

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%


DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future
Startup | October 01, 2025

DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future

India currently hosts more than 10,075 biotech startups


AstraZeneca to launch DTC medication platform, offering up to 70% discounts on Farxiga, Airsupra
Supply Chain | September 30, 2025

AstraZeneca to launch DTC medication platform, offering up to 70% discounts on Farxiga, Airsupra

The platform is being introduced to expand access to treatments for people living with chronic conditions


Gleneagles Hospital Mumbai and Medtronic host conclave on hub & spoke model and AI in healthcare
Healthcare | September 30, 2025

Gleneagles Hospital Mumbai and Medtronic host conclave on hub & spoke model and AI in healthcare

The Hub & Spoke model is designed to extend advanced medical care to a wider community


Apollo signs agreement to manage internal security force hospital in Iraq
Healthcare | September 29, 2025

Apollo signs agreement to manage internal security force hospital in Iraq

The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel


FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Drug Approval | September 29, 2025

FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor